EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Jason R Westin iD, Olalekan O Oluwole, Marie José Kersten, David B Miklos, Miguel-Angel Perales, Armin Ghobadi, Aaron P Rapoport, Anna Sureda, Caron A Jacobson, Umar Farooq, Tom van Meerten iD, Matthew Ulrickson und 20 weitere

New England Journal of Medicine · 13.07.2023 · 389 (2) · 148-157

DOI: 10.1056/nejmoa2301665 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 13.07.2023. Verfasst von Jason R Westin und 31 weiteren Autor:innen. Beteiligte Einrichtung: From University of Texas M.D. Anderson Cancer Center, Houston (J.R.W.); Vanderbilt-Ingram Cancer Center, Nashville (O.O.O.); Amsterdam University Med…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Biological Products, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 484-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: NCI NIH HHS, Kite, a Gilead Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalBiological ProductsLymphoma, Large B-Cell, DiffuseHumansAntigens, CD19Immunotherapy, AdoptiveSurvival Analysis

Substanzen

Antigens, CD19Antineoplastic Agents, Immunologicalaxicabtagene ciloleucelBiological Products

Autor:innen und Institutionen

  • From University of Texas M.D. Anderson Cancer Center, Houston (J.R.W.); Vanderbilt-Ingram Cancer Center, Nashville (O.O.O.); Amsterdam University Medical Center (UMC), University of Amsterdam, Cancer Center Amsterdam, A…

ORCID-Profile: Jason R Westin, Tom van Meerten, Michael Dickinson

Förderung

  • NCI NIH HHS
  • Kite, a Gilead Company

Zitieren

APA

Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M. A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., van Meerten, T., Ulrickson, M., Elsawy, M., Leslie, L. A., Chaganti, S., Dickinson, M., Dorritie, K., Reagan, P. M., McGuirk, J., …, & Kite Members (2023). Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. New England Journal of Medicine, 389(2), 148-157. https://doi.org/10.1056/nejmoa2301665

Vancouver

Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. New England Journal of Medicine. 2023;389(2):148-157. doi:10.1056/nejmoa2301665

BibTeX
@article{Westin2023,
  author = {Westin, Jason R and Oluwole, Olalekan O and Kersten, Marie José and Miklos, David B and Perales, Miguel-Angel and Ghobadi, Armin and Rapoport, Aaron P and Sureda, Anna and Jacobson, Caron A and Farooq, Umar and van Meerten, Tom and Ulrickson, Matthew and Elsawy, Mahmoud and Leslie, Lori A and Chaganti, Sridhar and Dickinson, Michael and Dorritie, Kathleen and Reagan, Patrick M and McGuirk, Joseph and Song, Kevin W and Riedell, Peter A and Minnema, Monique C and Yang, Yin and Vardhanabhuti, Saran and Filosto, Simone and Cheng, Paul and Shahani, Shilpa A and Schupp, Marco and To, Christina and Locke, Frederick L and ZUMA-7 Investigators, ZUMA-7 Investigators and Kite Members, Kite Members},
  title = {Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {2},
  pages = {148--157},
  doi = {10.1056/nejmoa2301665}
}
Kostenlos starten →